Member Info for ennombrede

Yes I hate it when the price of a stock I have goes down even a tad.
I remind myself that the presence of traders provides liquidity, thus tightening the bid:offer spread. When I make an investment in an illiquid stock it's a small one and I demand a cheaper valuation (known as Liquidity Premium).
I also, as well as plenty on this board, am very thankful to Jupiter and Legal General (see RNS 11th Sept 2020). I bought extra than I would have as there was a relative lack of buyside at the time, and these sellers wanted their own liquidity, as such it felt like a 'buyers market'. Thanks Sellers : )

How have I only done any research on MXCT, today?
Market dominant position in a new explosive market; only FDA approved in its niche; and superior product to the offerings from others such as Thermo Fisher. Consumables at 90% margin, and repeat business.
Does that remind me of another company??
I wonder if ppl will be discovering the company that need not be mentioned, in a year or two time and wondering... How did I miss that biz model?

Not investment advice. Just probably a thought that other holders may have, while we ponder what's attractive about some hot stocks that ppl today chase in the US for instance.

I think its important to not get too distracted by 'noise' here and there. Short term traders may well be jumping out of the way of shadows, or whatever the phrase is, but they tend to miss the structural fundamental picture sometimes.

When listening to the proactive investors presentation (available on Youtube) I heard something I considered comforting for the nervy, at 1hr 26mins in, in regard to their response to the AIR. I notice Sicilian Kan on a competing chat site has also pointed to it.

What we have here is of real interest to the likes of $200bn MktCap Abbott Labs.

Traders Cafe with Zak Mir: Interview with Andrew Newland, CEO Angle (AGL)
Sorry, it appears the link I posted doesnt show. The interview is available on the ********** website

https://www.**********.co.uk/articles/new-article-2b2aba2
Vox markets. Traders Cafe.

True.
I also can't see the smaller English PL clubs fancying this, especially if it's supposedly a division reduced to 18 teams.

Hi Cambridgeblue.
I wonder if there's any truth in this. The Big 6 in the English PL clearly want to enhance their income. Both Barca and Real Madrid have huge refinancing needs, and JP Morgan was willing to help assist in the European SL.
The Man City deal, with Silver Lake buying 10% of the equity for £369million is off-the scale compared to numbers in Scotland.
If Rangers and Celtic were to join the English PL this would be transformational for shareholders. But if they just continue to remain in the Scottish PL this financial gulf could get increasingly larger. Who knows Rangers and Celtic could get a huge financial boost, representing Scotland against the English and Welsh teams, and the rest of the Scottish PL might get a little more interesting for the neutral like me.
What do you think?

The Sun:
"FIRM FAVOURITES Rangers and Celtic are wanted in British Super League as part of secret plot after doomed ESL plan"
EXCLUSIVE
Martin Lipton
22 Apr 2021, 8:16Updated: 22 Apr 2021, 8:18

https://www.thescottishsun.co.uk/sport/football/7001508/rangers-celtic-wanted-british-league-fallout-european-super-league/

https://twitter.com/zerohedge/status/1340390069354573825
"BIDEN PROMISES 500,000 ELECTRIC VEHICLE CHARGING STATIONS"

Ive re-read my comments.
Errors include, Angle (still) HAVE a JV with Abbott
and I meant, US liquid biopsies focused on ctdna and molecular analysis as trying to get live intact CTCs is harder.

Yes. I'd add (https://www.youtube.com/watch?v=EsOdI__S-PU from 8mins in).

Angle had a JV with Abbott Labs ($190bn Market Cap). They currently have a test for HER-2 gene expression in breast cancer (which I think around half of patients have) from a solid tissue sample. Abbott will know that Liquid Biopsies should they be able to get the same information will be a cheaper, safer and repeatable method in the future. Competing US Liquid Biopsy companies focus on collecting dead fragments of dna. Whereas (as it was harder to collect) Angle can collect live intact CTCs, which the peer reviewed studies are showing can give the same info that Abbott and the physicians would want.

Page 13 of the 2019 Annual Report, shows that Abbott can increase its reimbursement here.

My wife unfortunately had a good friend who died recently as a result of metastasis. The original primary tumour was in the breast. Although that was successfully attacked, she ended up with a tumour in her brain. There's interesting research going on currently about CTC clusters which potentially is principle reason for this spread if I have understood it correctly. (Ive also read recently about how some drugs targeting a primary tumour, actually help spread CTC clusters(?) giving a worse outcome potentially)
I find Andrew Newland's comment from 8mins in, in this video (https://www.youtube.com/watch?v=lZTtbUSzufg) very interesting in regard to National Cancer guidelines for MBC cancer patients. It highlights a couple of the problems of trying to get tissue samples at all.

Anyway, I realise I digress. My point was actually to note that we already have a JV with Abbott who are gigantic, and both parties can benefit profit wise, as well as being able to conduct repeat liquid biopsies on patients throughout treatment.

Potential other partners are numerous. It was mentioned in a conference call that Abbott had asked for exclusivity.

Having said all that FDA approval is important in order to move forward.

A load of large trades earlier in the day have been reported after the close. That surely must be Jupiter out??

I'd imagine it will be straight after FDA approval, where they can clearly then get a good valuation, comparing themselves to US peers in a roadshow. Metastatic Breast Cancer alone is over a $2bn opportunity for AGL.

$2Bn x 70% Gross Margin is $1.4bn. EBIT maybe $1bn. Thus, if the stock trades at 8x EBIT, it'd be $8bn. Market Cap right now is just US$120mn. Finncap puts 80% probability on FDA approval.

That's just for Metastatic Breast Cancer; the evidence so far shows it works for the others.
Angle will be the only one in the market that can help monitor patients throughout their treatment and for drug development using intact live CTCs. The others are either years behind or focus on ctdna giving much less information.

https://youtu.be/EsOdI__S-PU
ANGLE completes FDA submission for Parsortix system for metastatic breast cancer
1min 24s in : 'several companies out there [US] have achieved investor valuations of multiple billions of dollars [Guardant Health (GH) $12bn, Exact Sciences (EXAS) $20bn, and Grail just bought by Illumina], and funnily enough we would say those companies are actually behind Angle'
You can get more information (such as RNA and protein analysis) from an intact CTC. See page 3+ in the Annual Report 2019 (https://angleplc.com/wp-content/uploads/4858_ANGLE_Plc_AR_December_2019_Hyperlink.pdf)

Angle once approved is targeting multiple billions of dollars in revenues at over 70% gross margin. The market cap is less than £100mn currently.

Agreed.
I've also been doing my fair slog of daily buying to help Jupiter out.

I'd caution any new buyers who are hoping to make a quick buck, to dyor on why actually this company could make a very good investment. Watch the videos of Angle plc on Proactiveinvestors Youtube; read the annual report; read the corporate news (RNS) such as peer reviewed studies using CTC capture and it's advantages over alternatives (what you can do vs Ctdna).
Peer group analysis shows US companies in the same space trading in the billions, who are not able to capture live CTCs. Angle outperforms any other in capturing live CTC's for subsequent analysis. Its a multi billion $ opportunity, and possible >70% operating profit margins. Look at what Angle has to offer for $190bn market cap Abbot Labs.

If you attribute a 80% chance of FDA approval during 2021 (Finncap est.) and such profitability, any price in the double digit pence may look ridiculous to you as it does to some of us long termers. But as always DYOR. If Jupiter aren't quite finished yet, does it really make much difference, unless that's what your trade is reliant on.

Personally I'm not sure that there's the evidenced volumes sufficient to fully clear it (unless virtually no one else is a seller) but I may be wrong.

Thank You

Anyone know which fund AGL is in?
Fincapp continues to provide supply, which is very nice of the seller(s) of course for the benefit of buyers and the terms of the Staff and Executive options, but (if its a fund that's not seeing net redemptions) I can't help think they've lost their marbles.
LGEN pensions too. Sorry if that seems rude to the fund manager(s) selling. Two sides to a market.

Nice to see some long termers still around. Though with the benefit of hindsight we could have simply invested after yesterday's RNS!

The MCap is pretty unbelievable.

It may be putting cold water on the suggestion that late IFN dosing could have a negative impact on Covid sufferers. Sadly I'm not medically trained, so any other opinions would be helpful.

Nature Published: 31 July 2020
COVID-19

ACE2 is not induced by interferon
Miriam Saffern
Nature Reviews Immunology (2020)

https://www.nature.com/articles/s41577-020-00416-8

Original article
Onabajo, O. O. et al. Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. Preprint at bioRxiv https://doi.org/10.1101/2020.07.19.210955 (2020)